TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02572128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortified rice
Description: Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortified rice
Description: Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2.
Study: NCT02436577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Description: Ticagrelor 90 mg OD tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Description: Ticagrelor 90 mg OD tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Description: Ticagrelor 90 mg OD tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Description: Ticagrelor 90 mg OD tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Description: Ticagrelor 90 mg OD tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Description: Ticagrelor 90 mg OD tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: Ticagrelor 90 mg OD tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: Ticagrelor 90 mg OD tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: Ticagrelor 90 mg OD tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: Ticagrelor 90 mg OD tablet, single dose
Study: NCT01764867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvoxamine
Description: Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study: NCT02436577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: Ticagrelor 90 mg OD tablet, single dose
Study: NCT00878462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE raspberry flavor (Treatment A)
Description: Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE raspberry flavor (Treatment A)
Description: Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE raspberry flavor (Treatment A)
Description: Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine RED raspberry flavor (Treatment B)
Description: Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine RED raspberry flavor (Treatment B)
Description: Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine RED raspberry flavor (Treatment B)
Description: Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine RED raspberry flavor (Treatment B)
Description: Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine RED raspberry flavor (Treatment B)
Description: Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine RED raspberry flavor (Treatment B)
Description: Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE UNFLAVORED (Treatment C)
Description: Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE UNFLAVORED (Treatment C)
Description: Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
Study: NCT01764867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study: NCT00878462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE UNFLAVORED (Treatment C)
Description: Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
Study: NCT01764867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study: NCT00934596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lund de-airing technique
Description: In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV \& Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbon-dioxide insufflation
Description: In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
Study: NCT02326974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Neoadjuvant treatment is for a total of 18 weeks.
Study: NCT02436577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor IR tablet (90 mg) administered with 150 mL of water
Description: Ticagrelor 90 mg IR tablet, single dose
Study: NCT02326974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Neoadjuvant treatment is for a total of 18 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of tumor/mastectomy
Description: Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
Study: NCT00966381

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise and weight loss intervention
Description: randomized control trial, stratified by parity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and weight loss intervention
Description: randomized control trial, stratified by parity
Study: NCT00894114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V520
Description: MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V520
Description: MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V520
Description: MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Comparator: ALVAC-HIV vaccine
Description: A single dose 0.1 intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: ALVAC-HIV vaccine
Description: A single dose 0.1 intramuscular injection
Study: NCT00878462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE UNFLAVORED (Treatment C)
Description: Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE UNFLAVORED (Treatment C)
Description: Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
Study: NCT02436577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor IR tablet (90 mg) administered with 150 mL of water
Description: Ticagrelor 90 mg IR tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor IR tablet (90 mg) administered with 150 mL of water
Description: Ticagrelor 90 mg IR tablet, single dose
Study: NCT02888080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
Study: NCT02436577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor IR tablet (90 mg) administered with 150 mL of water
Description: Ticagrelor 90 mg IR tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor IR tablet (90 mg) administered with 150 mL of water
Description: Ticagrelor 90 mg IR tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor IR tablet (90 mg) administered with 150 mL of water
Description: Ticagrelor 90 mg IR tablet, single dose
Study: NCT01641549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency surgery
Description: Emergency surgery (valve replacement or thrombectomy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinolytic therapy
Description: Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
Study: NCT02822664

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pedophiles patients
Description: cerebral MRI and/or cerebral PET imaging

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy subjects
Description: cerebral MRI and/or cerebral PET imaging

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MRI
Study: NCT02736071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Women will receive oral Celecoxib 200mg 2 hours before the procedure
Study: NCT02245334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: 1 pill per biopsy
Study: NCT04615299

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.
Study: NCT00894114

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: ALVAC-HIV vaccine
Description: A single dose 0.1 intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: ALVAC-HIV vaccine
Description: A single dose 0.1 intramuscular injection
Study: NCT04105777

Intervention type: DEVICE
Intervention: Parenteral Nutrition Bag Eurotube
Description: 7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.

Intervention type: DEVICE
Intervention: Parenteral Nutrition Bag Eurotube
Description: 7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.

Intervention type: DEVICE
Intervention: Parenteral Nutrition 2/3 chamber Bag
Description: Premixed 2/3-chamber bags which are eventually completed with other supplements shortly before administration by infusion into the bag.
Study: NCT01566526

Intervention type: DRUG
Intervention: dexamethasone intravitreal implant 0.7 mg
Description: OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
Study: NCT02762617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate intravaginal ring
Description: The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
Study: NCT05061342

Intervention type: OTHER
Intervention: No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic therapy, radiotherapy, Chinese traditional medicine, or palliative/supportive care.
Description: Any anticancer or palliative care
Study: NCT01426750

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren
Description: The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
Study: NCT00888979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotrol Inhaler
Description: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
Study: NCT00510601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kaneka Liposorber
Description: LDL-apheresis on a bi-weekly basis
Study: NCT00568542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoetin beta
Description: 35 I.E. kg body weight subcutaneous once per week for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 35 I.E. kg body weight placebo to erythropoetin beta
Study: NCT04347954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 2%
Description: Two sprays to each nare of PVP-I 2% via nasal spray bottle, four times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.5%
Description: Two sprays to each nare of PVP-I 0.5% via nasal spray bottle, four times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline 0.9%
Description: Two sprays to each nare of isotonic saline (0.9% NaCl) via nasal spray bottle, four times a day
Study: NCT00716144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talarozole
Description: Oral Capsule Once Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talarozole
Description: Oral Capsule Once Daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talarozole
Description: Oral Capsule Once Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Talarozole
Description: Oral Capsule Once Daily
Study: NCT03697616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ridge augmentation with sticky bone and GBR
Description: * Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~* Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~* Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~* For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~* Periosteal releasing incision will be done to provide flap advancement for tension free closure~* Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures
Study: NCT03890016

Intervention type: DIAGNOSTIC_TEST
Intervention: 20'Whole Blood ClottingTest (WBCT)
Description: 1ml of blood drawn from snake bite victims in clean glass test tubes of 1 cm diameter Kept undisturbed for a period of 20 minutes (measured by a stop watch). At the end of 20 minutes the tube is tilted to see if the blood has clotted or not.~If a well formed clot is not formed, the test is recorded as 'abnormal'.~If the clot seems well formed, it is further observed for a period of 30 minutes to look for dissolution of the formed clot and would be termed clot lysis. Clot lysis indicates an unstable clot.

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Lee and White (MLW) Method Clotting Time
Description: The blood collected in three additional test tubes would be utilised for MLW.~The three test tubes would be kept on a rack at ambient temperature.~The blood sample would be drawn in a 5cc syringe and 1 ml would be added in the three test tubes consecutively.~The test tube would be left undisturbed for 5 minutes, after that the first tube would be tilted approximately to check for clot formation every 30 seconds while the other tubes are left undisturbed.~After the blood in the first tube has clotted, the time would be noted and the second tube would be tilted every 30 seconds and examined.~Following its clotting, the third tube would be examined. The time at which the third tube is recorded as the CT value.~Once clotted, then the sample in the all three test tube would be assessed at 20 minute and 30 min to look for breakup or lysis of the clot.
Study: NCT03993613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human apotransferrin
Description: Intravenous infusions
Study: NCT01511172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1000 mg daily, administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: 1000 mg daily, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: 1000 mg daily, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Metformin placebo administered orally. 1000 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Individually adjusted dose, administered orally
Study: NCT02728440

Intervention type: DRUG
Intervention: human chorionic gonadotropin, human menopausal gonadotropin
Description: drug for the treatment of male hypogonadism
Study: NCT04051255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg
Description: The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg
Description: The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips\* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
Study: NCT02462551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Electrically Administered Seizure Therapy
Description: A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.